Satellos Bioscience Inc. (MSLE)
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Satellos Bioscience Inc. Common Stock
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Enrolling by invitation
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
SAT-3247
Duchenne Muscular Dystrophy (DMD)
NCT06867107Enrollment30StartAug 2025Primary CompletionSep 2027est.CompletionSep 2027est. - Phase 2Active, not recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
SAT-3247, Placebo
Duchenne Muscular Dystrophy, Duchenne +3
NCT07287189Enrollment51StartDec 2025Primary CompletionMar 2027est.CompletionFeb 2028est. - Phase 2Not yet recruiting
A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
forazapadin, Placebo Comparator
Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT07872306Enrollment51StartDec 2026est.Primary CompletionDec 2028est.CompletionJun 2029est. - Phase 1Completed
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
iCo-007 Intravitreal Injection
Diffuse Diabetic Macular Edema
NCT00886808Enrollment15StartFeb 2008Primary CompletionMay 2010CompletionJun 2010 - Early Phase 1Completed
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
SAT-3247, matched placebo
Duchenne Muscular Dystrophy
NCT06565208Enrollment77StartAug 2024Primary CompletionApr 2025CompletionApr 2025
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Enrolling by invitation | SAT-3247 | NCT06867107 |
| Phase 2 | Active, not recruiting | SAT-3247, Placebo | NCT07287189 |
| Phase 2 | Not yet recruiting | forazapadin, Placebo Comparator | NCT07872306 |
| Phase 1 | Completed | iCo-007 Intravitreal Injection | NCT00886808 |
| Early Phase 1 | Completed | SAT-3247, matched placebo | NCT06565208 |